ALK-ABELLÓ A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 125.6 DKK | 0.00% |
|
+0.80% | +24.11% |
| Mar. 14 | Transcript : ALK-Abelló A/S - Shareholder/Analyst Call | |
| Mar. 04 | New entries in MarketScreener's Europe portfolio |  |
| Sales 2024 * | 5.34B 760M | Sales 2025 * | 5.89B 839M | Capitalization | 27.78B 3.96B |
|---|---|---|---|---|---|
| Net income 2024 * | 763M 109M | Net income 2025 * | 1.07B 152M | EV / Sales 2024 * | 5.16 x |
| Net cash position 2024 * | 257M 36.57M | Net cash position 2025 * | 1.09B 155M | EV / Sales 2025 * | 4.53 x |
| P/E ratio 2024 * |
35.3
x | P/E ratio 2025 * |
26.6
x | Employees | 2,824 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on ALK-Abelló A/S
More press releases
| 1 day | -0.48% | ||
| 1 week | -0.32% | ||
| Current month | +1.21% | ||
| 1 month | -2.79% | ||
| 3 months | +10.18% | ||
| 6 months | +57.00% | ||
| Current year | +24.11% |
1 week
123.40
129.10
1 month
119.60130.20
Current year
98.50134.50
1 year
69.90134.50
3 years
69.90175.00
5 years
52.70175.00
10 years
29.25175.00
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Halling
CEO | Chief Executive Officer | 47 | Dec. 31 |
| Director of Finance/CFO | 52 | 23-05-31 | |
| Chief Tech/Sci/R&D Officer | - | 23-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 57 | 21-03-17 | |
Anders Hedegaard
CHM | Chairman | 63 | 20-03-10 |
| Director/Board Member | 64 | 15-03-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.24% | 2 M€ | -.--% | ||
| 0.09% | 7 M€ | -.--% | - | |
| 0.03% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 125.6 | 0.00% | 148 646 |
| 24-04-18 | 125.6 | -0.48% | 185,929 |
| 24-04-17 | 126.2 | -0.86% | 126,778 |
| 24-04-16 | 127.3 | -1.01% | 233,099 |
| 24-04-15 | 128.6 | +3.21% | 194,181 |
Delayed Quote Nasdaq Copenhagen, April 18, 2024 at 10:59 am EDT
More quotes
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Companyâs allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
125.6
DKK
Average target price
125
DKK
Spread / Average Target
-0.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.11% | 3.97B | |
| +27.97% | 672B | |
| +23.58% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.96% | 211B | |
| -0.41% | 203B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- ALK B Stock
